$INTI
Inhibitor Therapeutics, Inc.

2013 Q4 Form 10-Q Financial Statement

#000119312513442198 Filed on November 14, 2013

View on sec.gov

Income Statement

Concept 2013 Q4 2013 Q3 2012 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $200.0K $240.0K $110.0K
YoY Change -16.67% 118.18% -21.43%
% of Gross Profit
Research & Development $20.00K $1.050M
YoY Change
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $210.0K $1.292M $137.5K
YoY Change -12.5% 840.17% -1.81%
Operating Profit -$1.292M -$137.5K
YoY Change 840.17%
Interest Expense $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
% of Operating Profit
Other Income/Expense, Net $90.00K
YoY Change -40.0%
Pretax Income -$220.0K -$1.290M $640.0K
YoY Change 0.0% -301.56% -1700.0%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$220.0K -$1.292M $640.3K
YoY Change 0.0% -301.85% -1700.72%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$0.01 -$0.07 $0.05
COMMON SHARES
Basic Shares Outstanding 18.89M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q4 2013 Q3 2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $0.00 $0.00 $920.0K
YoY Change -100.0% -100.0% 1214.29%
Cash & Equivalents $217.00 $112.00 $923.4K
Short-Term Investments $0.00
Other Short-Term Assets $0.00 $50.00K
YoY Change -100.0% 400.0%
Inventory
Prepaid Expenses $10.00K
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $10.22K $112.00 $980.0K
YoY Change -98.91% -99.99% 988.89%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $10.22K $112.00 $980.0K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $10.22K $112.00 $980.0K
YoY Change -98.91% -99.99% -73.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $287.1K $233.3K $220.0K
YoY Change -22.12% 6.03% 214.29%
Accrued Expenses $0.00 $0.00 $170.0K
YoY Change -100.0% -100.0% 41.67%
Deferred Revenue
YoY Change
Short-Term Debt $70.00K $70.00K $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $776.1K $550.8K $400.0K
YoY Change 38.59% 37.69% 100.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $0.00 $0.00 $480.0K
YoY Change -100.0% -100.0% -44.19%
Total Long-Term Liabilities $0.00 $0.00 $480.0K
YoY Change -100.0% -100.0% -87.23%
TOTAL LIABILITIES
Total Short-Term Liabilities $776.1K $550.8K $400.0K
Total Long-Term Liabilities $0.00 $0.00 $480.0K
Total Liabilities $776.1K $550.8K $890.0K
YoY Change -27.42% -38.11% -77.53%
SHAREHOLDERS EQUITY
Retained Earnings -$28.25M -$28.03M
YoY Change 6.95%
Common Stock $1.889K $1.889K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$765.8K -$550.7K $90.00K
YoY Change
Total Liabilities & Shareholders Equity $10.22K $112.00 $980.0K
YoY Change -98.91% -99.99% -73.8%

Cashflow Statement

Concept 2013 Q4 2013 Q3 2012 Q3
OPERATING ACTIVITIES
Net Income -$220.0K -$1.292M $640.3K
YoY Change 0.0% -301.85% -1700.72%
Depreciation, Depletion And Amortization $0.00
YoY Change -100.0%
Cash From Operating Activities -$170.0K -$120.0K -$230.0K
YoY Change 183.33% -47.83% -483.33%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 170.0K 130.0K 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -170.0K -120.0K -230.0K
Cash From Investing Activities 0.000
Cash From Financing Activities 170.0K 130.0K 0.000
Net Change In Cash 0.000 10.00K -230.0K
YoY Change -100.0% -104.35% 1050.0%
FREE CASH FLOW
Cash From Operating Activities -$170.0K -$120.0K -$230.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1321968
CY2012Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15560504 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15560504 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2012Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q4 us-gaap Liabilities Subject To Compromise
LiabilitiesSubjectToCompromise
509266
CY2012Q4 us-gaap Liabilities Subject To Compromise Other Liabilities
LiabilitiesSubjectToCompromiseOtherLiabilities
63500
CY2012Q4 us-gaap Liabilities Subject To Compromise Accounts Payable And Accrued Liabilities
LiabilitiesSubjectToCompromiseAccountsPayableAndAccruedLiabilities
422316
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
26279815
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
368613
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
559953
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-132784
CY2012Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
191340
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-26412599
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
936435
CY2012Q4 us-gaap Liabilities
Liabilities
1069219
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2012Q4 us-gaap Assets Current
AssetsCurrent
936435
CY2012Q4 us-gaap Assets
Assets
936435
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
857702
CY2012Q4 us-gaap Other Assets Current
OtherAssetsCurrent
78733
CY2012Q4 hppi Liabilities Subject To Compromise Priority Claims
LiabilitiesSubjectToCompromisePriorityClaims
23450
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
923418
CY2013Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18888971 shares
CY2013Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18888971 shares
CY2013Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
9500000 shares
CY2013Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
340000000 shares
CY2013Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2013Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2013Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
27479913
CY2013Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
233263
CY2013Q3 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
68428
CY2013Q3 us-gaap Liabilities Current
LiabilitiesCurrent
550779
CY2013Q3 us-gaap Stockholders Equity
StockholdersEquity
-550667
CY2013Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
196588
CY2013Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-28032486
CY2013Q3 us-gaap Common Stock Value
CommonStockValue
1889
CY2013Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
112
CY2013Q3 us-gaap Liabilities
Liabilities
550779
CY2013Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
52500
CY2013Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q3 us-gaap Assets Current
AssetsCurrent
112
CY2013Q3 us-gaap Assets
Assets
112
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112
CY2013Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
0
CY2013Q3 hppi Working Capital Advances From Affiliates
WorkingCapitalAdvancesFromAffiliates
62000
CY2013Q3 hppi Maximum Expected Equity Fund From Public Private And Other Financing Transaction
MaximumExpectedEquityFundFromPublicPrivateAndOtherFinancingTransaction
5000000
CY2013Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
18888971 shares
dei Entity Registrant Name
EntityRegistrantName
HedgePath Pharmaceuticals, Inc.
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2013-09-30
dei Entity Central Index Key
EntityCentralIndexKey
0001042418
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P3Y
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17620984 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
1.00 pure
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1054178
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
0 shares
hppi Period Consider For Average Equity Stock Price Calculation Per Share
PeriodConsiderForAverageEquityStockPriceCalculationPerShare
P30D
hppi Sharebased Compensation Arrangement Purchase Price Of Common Stock Percent Related To Specific Voting Stock Percentage
SharebasedCompensationArrangementPurchasePriceOfCommonStockPercentRelatedToSpecificVotingStockPercentage
1.10 pure
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-527
hppi Minimum Specified Voting Stock Percentage Under Incentive Stock Plan
MinimumSpecifiedVotingStockPercentageUnderIncentiveStockPlan
0.10 pure
hppi Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period Related To Specific Voting Stock Percentage
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodRelatedToSpecificVotingStockPercentage
P5Y
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <i>Estimates</i></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</p> </div>
us-gaap Revenues
Revenues
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
152000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-78733
us-gaap Operating Income Loss
OperatingIncomeLoss
-1786563
us-gaap Net Income Loss
NetIncomeLoss
-1619887
us-gaap Notes Issued1
NotesIssued1
68428
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1050004
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
619235
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
196588
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-9087
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-857590
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1050004
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
196588
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
us-gaap Operating Expenses
OperatingExpenses
1786563
hppi Reorganization And Other Expenses
ReorganizationAndOtherExpenses
117324
hppi In Process Research And Development Paid In Stock
InProcessResearchAndDevelopmentPaidInStock
1020004
hppi Net Cash Provided By Operating Activities Before Reorganization Items
NetCashProvidedByOperatingActivitiesBeforeReorganizationItems
-530237
hppi Increase Decrease In Liabilities Subject To Compromise
IncreaseDecreaseInLiabilitiesSubjectToCompromise
-357265
hppi Gain Loss On Reorganization
GainLossOnReorganization
166676
hppi Stock Payment In Lieu Of Cash
StockPaymentInLieuOfCash
152000
hppi Bankruptcy Claims Settlement In Cash
BankruptcyClaimsSettlementInCash
357265
hppi Bankruptcy Claims Settlement In Equity
BankruptcyClaimsSettlementInEquity
152000
hppi Supply And License Agreement Term Duration From First Commercial Transaction
SupplyAndLicenseAgreementTermDurationFromFirstCommercialTransaction
P10Y
hppi Gain Loss On Reorganization And Extinguishment Of Debt
GainLossOnReorganizationAndExtinguishmentOfDebt
166676
hppi Deposit Reclassified To Preferred Stock
DepositReclassifiedToPreferredStock
30000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13004026 shares
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-398550
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.03
us-gaap Revenues
Revenues
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
1084
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
687500
us-gaap Operating Income Loss
OperatingIncomeLoss
-353926
us-gaap Net Income Loss
NetIncomeLoss
410953
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
322301
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-171446
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-398550
us-gaap Interest Expense
InterestExpense
20833
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
us-gaap Operating Expenses
OperatingExpenses
353926
hppi Reorganization And Other Expenses
ReorganizationAndOtherExpenses
31625
hppi Stock Issuance Costs
StockIssuanceCosts
50000
hppi Net Cash Provided By Operating Activities Before Reorganization Items
NetCashProvidedByOperatingActivitiesBeforeReorganizationItems
-398550
hppi Gain Loss On Reorganization And Extinguishment Of Debt
GainLossOnReorganizationAndExtinguishmentOfDebt
785712
CY2013Q1 hppi Percentage Of Issued And Outstanding Shares Of Common Stock
PercentageOfIssuedAndOutstandingSharesOfCommonStock
1.00 pure
CY2013Q1 hppi Ownership Exchanged For Assets Contributed
OwnershipExchangedForAssetsContributed
0.90 pure
CY2013Q2 us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
3328467 shares
CY2013Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
152000
CY2013Q2 hppi Period Consider For Average Equity Stock Price Calculation Per Share
PeriodConsiderForAverageEquityStockPriceCalculationPerShare
P30D
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13683602 shares
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.05
CY2012Q3 us-gaap Revenues
Revenues
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-137469
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
640287
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
107469
CY2012Q3 us-gaap Operating Expenses
OperatingExpenses
137469
CY2012Q3 hppi Reorganization And Other Expenses
ReorganizationAndOtherExpenses
30000
CY2012Q3 hppi Gain Loss On Reorganization And Extinguishment Of Debt
GainLossOnReorganizationAndExtinguishmentOfDebt
777756
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18888971 shares
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
CY2013Q3 us-gaap Revenues
Revenues
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1292439
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-1292439
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
242435
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1050004
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
1292439

Files In Submission

Name View Source Status
0001193125-13-442198-index-headers.html Edgar Link pending
0001193125-13-442198-index.html Edgar Link pending
0001193125-13-442198.txt Edgar Link pending
0001193125-13-442198-xbrl.zip Edgar Link pending
d598248d10q.htm Edgar Link pending
d598248dex311.htm Edgar Link pending
d598248dex312.htm Edgar Link pending
d598248dex321.htm Edgar Link pending
d598248dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hppi-20130930.xml Edgar Link completed
hppi-20130930.xsd Edgar Link pending
hppi-20130930_cal.xml Edgar Link unprocessable
hppi-20130930_def.xml Edgar Link unprocessable
hppi-20130930_lab.xml Edgar Link unprocessable
hppi-20130930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending